Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
Michelle R Lofwall, Sharon L Walsh, George E Bigelow...
https://pubmed.ncbi.nlm.nih.gov/17605004/Actively Recruiting
Led by Adneuris Therapeutics, Inc. · Updated on 2026-10-23
45
Participants Needed
2
Research Sites
13 weeks
Total Duration
Researchers are evaluating cebranopadol, a drug, to see if multiple doses can reduce opioid withdrawal signs and symptoms in adults with chronic pain who are physically dependent on prescribed opioids. This Phase 2 trial compares two different dosing schedules of cebranopadol with a placebo. The study also examines pain levels, safety, tolerability, and how the drug is processed by the body. Participants will first complete outpatient screening, then be admitted as inpatients for treatment. Their current opioid will be stopped after the morning dose on Day -1 to confirm withdrawal symptoms using specific scales. Those who meet withdrawal criteria will resume opioids briefly before being randomly assigned to one of two cebranopadol dosing regimens or placebo. The study drug is given orally every 12 hours for 48 hours during inpatient stay. Rescue medication is available if needed, and participants resume their prescribed opioids at least 12 hours after the last study dose. During the inpatient treatment, participants undergo assessments for withdrawal, pain, safety, and drug levels. After treatment, they stay monitored until discharge on Day 4. A safety follow-up call is conducted around Day 7. Researchers measure withdrawal severity using the Clinical Opiate Withdrawal Scale over 48 hours as the main outcome, along with other measures of pain, medication use, and safety. The total participation lasts about one week.
CONDITIONS
A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain
S
Study Director Adneuris Therapeutics
C
Clinical Development Adneuris Therapeutics
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Adneuris Therapeutics, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational Cebranopadol | Placebo comparator | Current standard (buprenorphine) |
|---|---|---|---|
| What it is | Oral investigational analgesic Cebranopadol administered twice daily at target doses of approximately 600 or 800 µg per day | Oral placebo given twice daily matching the dosing schedule of the investigational drug | Buprenorphine is a nationally accepted partial opioid agonist used to manage opioid withdrawal symptoms |
| Role in the trial | Tested at two dose levels as active intervention in randomized comparison | Placebo control arm for randomized efficacy comparison | Serves as common clinical benchmark for opioid withdrawal management |
| Primary use | Studied for reduction of opioid withdrawal symptoms in adults with chronic pain and physical dependence | Inactive control to assess efficacy of investigational drug | Used to alleviate opioid withdrawal symptoms and transition patients to maintenance therapy |
| How it is given or performed | Orally administered twice daily starting on Day 1 through study dosing schedule | Orally administered placebo twice daily on the same schedule | Typically initiated under medical supervision with sublingual or injectable formulations as opioid agonist replacement |
| Evidence status | Efficacy under investigation; no published results yet | Serves as control; no expectation of efficacy | Supported by clinical use and systematic evaluations for reducing withdrawal severity |
| Important risks | Unknown; safety profile will be evaluated within trial | Generally no pharmacologic risk from inactive placebo | Known risks include precipitated withdrawal, sedation, potential for diversion or misuse |
| Important limitations | Efficacy and safety not yet established; adult chronic pain population only | Does not represent active treatment; only serves for comparison | Not tested in this trial; applicability may differ in chronic pain patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 30 days
Participants are screened for eligibility including outpatient assessments and physical opioid dependence confirmation.
Outpatient screening visits
Duration - 3 days
Participants stop their prescribed opioids to confirm withdrawal, then are randomized to receive cebranopadol or placebo for 48 hours while inpatient. Withdrawal, pain, safety, and drug levels are assessed. Rescue medication is available if needed.
Continuous inpatient monitoring during treatment
Duration - 1 day
A telephone call is made around Day 7 to check safety after the last study drug dose.
1 telephone call
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Michelle R Lofwall, Sharon L Walsh, George E Bigelow...
https://pubmed.ncbi.nlm.nih.gov/17605004/Maria Alexandra Ferreira-Valente, José Luís Pais-Ribeiro, Mark P Jensen
https://pubmed.ncbi.nlm.nih.gov/21856077/Donald R Wesson, Walter Ling
https://pubmed.ncbi.nlm.nih.gov/12924748/Marianne Jensen Hjermstad, Peter M Fayers, Dagny F Haugen...
https://pubmed.ncbi.nlm.nih.gov/21621130/Stacey C Sigmon, Conrad J Wong, Allison L Chausmer...
https://pubmed.ncbi.nlm.nih.gov/15500597/Michelle R Lofwall, Shanna Babalonis, Paul A Nuzzo...
https://pubmed.ncbi.nlm.nih.gov/27234658/Adneuris Therapeutics, Inc.
Lead Sponsor